#Ophthalmology #clinicaltrial #dryAMDtreatment #PST611 #PulseSightTherapeutics #phase1safetystudy #genetherapy #geographicatrophy #GA #nonviralgenetherapy #dryagerelatedmaculardegeneration #AMD #DryAMD #PST611CT1study #electrotransfectiontechnology #DNAplasmids
pharmatimes.com/news/first-p...
pharmatimes.com/news/first-p...
First patient dosed in trial for novel dry AMD treatment PST-611 - PharmaTimes
PulseSight begins phase 1 safety study of gene therapy for geographic atrophy
pharmatimes.com
July 10, 2025 at 10:17 AM